American Health & Drug Benefits

Recent Articles

Business, Original Research

Employer Disability and Workers’ Compensation Trends for Their Employees With Ophthalmic Conditions in the United States

Richard A. Brook, MS, MBA; Nathan L. Kleinman, PhD; Ian A. Beren, BS

In the News

Tornado Sweeps Through Pfizer’s Storage and Manufacturing Facility

In the News

Acceptance of Artificial Intelligence in Healthcare Is Making Inroads

Recent FDA Approvals

FDA Approvals

FDA Approved Izervay for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration

FDA Approvals

FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM

FDA Approvals

FDA Approved Xdemvy, First Treatment for Demodex Blepharitis

Most Popular Articles

Business, Original Research

Trends in Utilization, Prices, and Spending for Oral Medications for Breast Cancer Treatment in the US Medicaid Population, 2008-2019

Fatimah Alyami, MS, PhD; Jeff Jianfei Guo, BPharm, PhD

FDA Approvals

Epkinly FDA Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma

FDA Approvals

Lynparza FDA Approved, in Combination With Abiraterone and Prednisone (or Prednisolone), for Metastatic Castration-Resistant Prostate Cancer With BRCA Mutation

FDA Approvals

FDA Accelerated the Approval of Columvi for Selected Relapsed or Refractory Large B-Cell Lymphomas

Business, Original Research

Employer Disability and Workers’ Compensation Trends for Their Employees With Ophthalmic Conditions in the United States

Richard A. Brook, MS, MBA; Nathan L. Kleinman, PhD; Ian A. Beren, BS

FDA Approvals

Talzenna Received a New Indication, With Enzalutamide, for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Mutation

SUBSCRIBE

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Special Print Editions

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.